Shanghai Henlius Biotech (2696) Stock Overview

Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. More details

2696 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	3/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 63.7% below our estimate of its fair value

Earnings are forecast to grow 11.6% per year

Earnings have grown 66% per year over the past 5 years

Analysts in good agreement that stock price will rise by 63.6%

Risk Analysis

Has a high level of debt

2696 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Shanghai Henlius Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Henlius Biotech
Historical stock prices
Current Share Price	HK$62.75
52 Week High	HK$92.00
52 Week Low	HK$48.30
Beta	0.51
1 Month Change	-11.31%
3 Month Change	-6.55%
1 Year Change	22.20%
3 Year Change	467.36%
5 Year Change	60.49%
Change since IPO	26.90%

Recent News & Updates

Analysis Article • Jun 20

Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals

Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its HANSIZHUANG immunotherapy. See our latest analysis for Shanghai Henlius Biotech. These regulatory approvals arrive after a mixed stretch for Shanghai Henlius Biotech’s stock, with the share price up 7.51% year to date but down 11.45% over the past month. The 1-year total shareholder return of...

Recent updates

Analysis Article • Jun 20

Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals

Analysis Article • May 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analysis Article • Mar 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

A week ago, Shanghai Henlius Biotech, Inc. ( HKG:2696 ) came out with a strong set of full-year numbers that could...

Analysis Article • Mar 10

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc.'s ( HKG:2696 ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong...

Shareholder Returns

	2696	HK Biotechs	HK Market
7D	4.8%	-4.1%	-4.5%
1Y	22.2%	-10.2%	2.0%

Return vs Industry: 2696 exceeded the Hong Kong Biotechs industry which returned -10.2% over the past year.

Return vs Market: 2696 exceeded the Hong Kong Market which returned 2% over the past year.

Price Volatility

Is 2696's price volatile compared to industry and market?
2696 volatility
2696 Average Weekly Movement	8.5%
Biotechs Industry Average Movement	8.6%
Market Average Movement	7.4%
10% most volatile stocks in HK Market	16.1%
10% least volatile stocks in HK Market	3.6%

Stable Share Price: 2696 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2696's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2010	3,762	Jason Zhu	www.henlius.com

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease, and pediatric Crohn’s disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma.

Shanghai Henlius Biotech, Inc. Fundamentals Summary

How do Shanghai Henlius Biotech's earnings and revenue compare to its market cap?
2696 fundamental statistics
Market cap	HK$33.23b
Earnings (TTM)	HK$956.53m
Revenue (TTM)	HK$7.71b

35.7x

P/E Ratio

4.4x

P/S Ratio

Is 2696 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2696 income statement (TTM)
Revenue	CN¥6.67b
Cost of Revenue	CN¥1.68b
Gross Profit	CN¥4.98b
Other Expenses	CN¥4.16b
Earnings	CN¥827.04m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	1.52
Gross Margin	74.77%
Net Profit Margin	12.41%
Debt/Equity Ratio	86.8%

How did 2696 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/23 18:23
End of Day Share Price	2026/06/23 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai Henlius Biotech, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yang Huang	BofA Global Research
Pei Cheng	China Galaxy Securities Co., Ltd.
Bo Yu	China International Capital Corporation Limited

Shanghai Henlius Biotech (2696) Stock Overview

Rewards

Risk Analysis

Shanghai Henlius Biotech, Inc. Competitors

3SBio

Biocytogen Pharmaceuticals (Beijing)

InnoCare Pharma

RemeGen

Price History & Performance

Recent News & Updates

Organon Canada and Shanghai Henlius Biotech Launch Bildyos (Denosumab Injection) and Tuzemty (Denosumab Injection) Biosimilars in Canada

Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals

Shanghai Henlius Biotech Doses First Patient in International Multi-Center Phase 1 Clinical Study of Biosimilar Pembrolizumab Hlx17

Shanghai Henlius Biotech Gains China Approval for HANBEIYOU Raising Valuation Questions

Shanghai Henlius Biotech, Inc. Announces Approval Of HANBEIYOU Pertuzumab In China For HER2-Positive Breast Cancer

Shanghai Henlius Biotech Announces Approval Of Hanbeiyou Pertuzumab Injection For Neoadjuvant Adjuvant Treatment Of Her2-Positive Early Breast Cancer And Treatment Of Metastatic Breast Cancer

Recent updates

Organon Canada and Shanghai Henlius Biotech Launch Bildyos (Denosumab Injection) and Tuzemty (Denosumab Injection) Biosimilars in Canada

Shanghai Henlius Biotech (SEHK:2696) Stock Could Be Worth A Look After China Oncology Approvals

Shanghai Henlius Biotech Doses First Patient in International Multi-Center Phase 1 Clinical Study of Biosimilar Pembrolizumab Hlx17

Shanghai Henlius Biotech Gains China Approval for HANBEIYOU Raising Valuation Questions

Shanghai Henlius Biotech, Inc. Announces Approval Of HANBEIYOU Pertuzumab In China For HER2-Positive Breast Cancer

Shanghai Henlius Biotech Announces Approval Of Hanbeiyou Pertuzumab Injection For Neoadjuvant Adjuvant Treatment Of Her2-Positive Early Breast Cancer And Treatment Of Metastatic Breast Cancer

Shanghai Henlius Biotech, Inc. Doses First Patient in International Multicenter Phase 1 Clinical Study of HLX15-SC for First-Line Treatment of Newly Diagnosed Multiple Myeloma in Chinese Mainland

Shanghai Henlius Biotech, Inc. and Organon Receive European Commission Approval for Poherdy Pertuzumab

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 19, 2026

Investor sentiment improves as stock rises 16%

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Shanghai Henlius Biotech, Inc. to Report Fiscal Year 2025 Results on Mar 20, 2026

Shanghai Henlius Biotech, Inc. Announces Investigational New Drug Application for Phase 1 Clinical Trial of HLX15-SC

Investor sentiment improves as stock rises 20%

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX43 for Injection with HLX07

Investor sentiment deteriorates as stock falls 15%

Shanghai Henlius Biotech, Inc. Announces Investigational New Drug Application for A Phase 1B/2 Clinical Trial of HLX701

Shanghai Henlius Biotech, Inc. Announces the Biologics License Application for Bevacizumab Injection

Investor sentiment improves as stock rises 16%

Shanghai Henlius Biotech, Inc. Announces Investigational New Drug Application for the Phase 1 Clinical Trial of Nivolumab Biosimilar Hlx18

Shanghai Henlius Biotech, Inc. and Organon Announce US FDA Approval of POHERDY®? (pertuzumab-dpzb) Biosimilar in the US

Shanghai Henlius Biotech, Inc. Announces Phase 3 Clinical Study of HANSIZHUANG (Serplulimab Injection) in Combination with Chemotherapy for Neo-/Adjuvant Treatment for Gastric Cancer

First half 2025 earnings released: EPS: CN¥0.72 (vs CN¥0.71 in 1H 2024)

European Commission Approves Henlius and Organon's Bildyos®? (Denosumab) and Bilprevda®? (Denosum Ab) and Xgeva (Denosumab), Respectively

US Food and Drug Administration Approves Henlius and Organon's BILDYOS®? (denosumab-nxxp) and BILPREVDA®? (denosumAb)

Consensus EPS estimates fall by 25%

Shanghai Henlius Biotech, Inc. Announces Board and Committee Changes

First half 2025 earnings released: EPS: CN¥0.72 (vs CN¥0.71 in 1H 2024)

Shanghai Henlius Biotech, Inc. Announces First Patient in the United States Has Been Dosed in an International Multi-Center Phase 2 Clinical Study of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. to Report First Half, 2025 Results on Aug 25, 2025

Investor sentiment improves as stock rises 20%

Shanghai Henlius Biologics Co., Ltd. Receives the Certificates of GMP Compliance of a Manufacturer Issued by the Federal Agency for Medicines and Health Products in Belgium

Shanghai Henlius Biotech, Inc. Announces Change in Nomination Committee with Effect from 27 June 2025

Shanghai Henlius Biotech, Inc. Controlling Subsidiary of Henlius Europe Gmbh Receives Letter from the European Commission in Relation to Hlx22

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 19%

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in Phase 2 Clinical Study of HLX22

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 08, 2025

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1B/2 Clinical Trial of HLX43 for Injection

Investor sentiment deteriorates as stock falls 22%

Shanghai Henlius Biotech, Inc. Announces Phase 3 Clinical Study of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection HLX04-O

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (Pertuzumab) Biosimilar Candidate HLX11

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx79 Injection

Full year 2024 earnings released: EPS: CN¥1.51 (vs CN¥1.01 in FY 2023)

Shanghai Henlius Biotech, Inc. Announces Re-Designation of Wenjie Zhang from Executive Director to A Non-Executive Director

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

Shanghai Henlius Biotech, Inc. to Report Fiscal Year 2024 Results on Mar 24, 2025

Investor sentiment improves as stock rises 32%

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 2 Clinical Study of HLX43 for Injection

Investor sentiment improves as stock rises 20%

Shanghai Henlius Biotech, Inc. Announces Biologics License Application Forpertuzumab Biosimilar Hlx11(Recombinant Anti-Her2 Domain II Humanizedmonoclonal Antibody Injection) Accepted by the United States Food and Drug Administration

Investor sentiment deteriorates as stock falls 17%

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Phase 1B/2 Clinical Trial of Hlx43 for Injection (Antibody-Drug Conjugate Targetingpd-L1 with Novel Dna Topoisomerase I Inhibitor) in Combination with Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient in Mainland China Dosed in an International Multi-Center Phase 3 Clinical Study

New major risk - Revenue and earnings growth

Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)